Journal
BIOSCIENCE REPORTS
Volume 34, Issue -, Pages 487-U205Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BSR20140071
Keywords
crystallography; DAAO; DAO; drug discovery; NMDA receptor; schizophrenia
Categories
Funding
- Sunovion Pharmaceuticals
- Fondo di Ateneo per la Ricerca, University of Insubria
Ask authors/readers for more resources
The NMDAR (N-methyl-D-aspartate receptor) is a central regulator of synaptic plasticity and learning and memory. hDAA0 (human D-amino acid oxidase) indirectly reduces NMDAR activity by degrading the NMDAR co-agonist D-serine. Since NMDAR hypofunction is thought to be a foundational defect in schizophrenia, hDAA0 inhibitors have potential as treatments for schizophrenia and other nervous system disorders. Here, we sought to identify novel chemicals that inhibit hDAA0 activity. We used computational tools to design a focused, purchasable library of compounds. After screening this library for hDAA0 inhibition, we identified the structurally novel compound, 'compound 2' [3-(7-hydroxy-2-oxo-4-phenyl-2H-chromen-6-yl)propanoic acid], which displayed low nM hDAA0 inhibitory potency (K-i = 7 nM). Although the library was expected to enrich for compounds that were competitive for both D-serine and FAD, compound 2 actually was FAD uncompetitive, much like canonical hDAA0 inhibitors such as benzoic acid. Compound 2 and an analog were independently co-crystalized with hDAAO. These compounds stabilized a novel conformation of hDAA0 in which the active-site lid was in an open position. These results confirm previous hypotheses regarding active-site lid flexibility of mammalian D-amino acid oxidases and could assist in the design of the next generation of hDAA0 inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available